Shiv Tej Sehra, M.B.,B.S.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Geographic Information Systems | 2 | 2020 | 283 | 1.220 |
Why?
|
| Communicable Disease Control | 2 | 2020 | 856 | 0.900 |
Why?
|
| Gout | 4 | 2024 | 620 | 0.880 |
Why?
|
| Weather | 1 | 2020 | 234 | 0.650 |
Why?
|
| Contact Tracing | 1 | 2020 | 274 | 0.600 |
Why?
|
| Sulfasalazine | 1 | 2018 | 85 | 0.580 |
Why?
|
| KATP Channels | 1 | 2017 | 49 | 0.550 |
Why?
|
| Arthritis, Psoriatic | 1 | 2019 | 219 | 0.530 |
Why?
|
| Scleroderma, Systemic | 2 | 2017 | 346 | 0.500 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 560 | 0.480 |
Why?
|
| Travel | 1 | 2020 | 805 | 0.470 |
Why?
|
| Hyaluronic Acid | 1 | 2018 | 484 | 0.460 |
Why?
|
| Bone Density Conservation Agents | 1 | 2021 | 797 | 0.440 |
Why?
|
| Arthritis | 1 | 2018 | 684 | 0.400 |
Why?
|
| Osteoporosis | 1 | 2021 | 1604 | 0.380 |
Why?
|
| Sulfonylurea Compounds | 1 | 2011 | 220 | 0.330 |
Why?
|
| Mortality | 1 | 2020 | 2909 | 0.310 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2017 | 3249 | 0.200 |
Why?
|
| Hospital Mortality | 1 | 2016 | 5345 | 0.190 |
Why?
|
| Uricosuric Agents | 1 | 2020 | 30 | 0.180 |
Why?
|
| Blood Sedimentation | 1 | 2020 | 235 | 0.160 |
Why?
|
| Sunlight | 1 | 2020 | 337 | 0.160 |
Why?
|
| Chikungunya virus | 1 | 2019 | 56 | 0.160 |
Why?
|
| Hyperuricemia | 1 | 2021 | 221 | 0.160 |
Why?
|
| Gout Suppressants | 1 | 2020 | 176 | 0.150 |
Why?
|
| Hypoglycemic Agents | 1 | 2011 | 3108 | 0.150 |
Why?
|
| World Health Organization | 1 | 2024 | 1327 | 0.150 |
Why?
|
| Necrosis | 1 | 2021 | 1614 | 0.140 |
Why?
|
| Placebo Effect | 1 | 2020 | 516 | 0.130 |
Why?
|
| Infusions, Intravenous | 1 | 2021 | 2227 | 0.130 |
Why?
|
| Government Regulation | 1 | 2020 | 525 | 0.130 |
Why?
|
| Diphosphonates | 1 | 2021 | 633 | 0.130 |
Why?
|
| Ultraviolet Rays | 1 | 2020 | 1101 | 0.120 |
Why?
|
| Arthralgia | 1 | 2019 | 459 | 0.120 |
Why?
|
| Pennsylvania | 1 | 2016 | 615 | 0.120 |
Why?
|
| Cost of Illness | 1 | 2024 | 1951 | 0.120 |
Why?
|
| Incidence | 2 | 2024 | 21526 | 0.110 |
Why?
|
| Temperature | 1 | 2020 | 2232 | 0.110 |
Why?
|
| Rheumatology | 1 | 2020 | 617 | 0.110 |
Why?
|
| Comorbidity | 2 | 2020 | 10582 | 0.110 |
Why?
|
| United States | 5 | 2020 | 72971 | 0.110 |
Why?
|
| Rheumatoid Factor | 1 | 2014 | 185 | 0.110 |
Why?
|
| Fever | 1 | 2019 | 1605 | 0.100 |
Why?
|
| Cardiovascular Diseases | 1 | 2017 | 15645 | 0.090 |
Why?
|
| Headache | 1 | 2019 | 1261 | 0.090 |
Why?
|
| Humans | 17 | 2024 | 767040 | 0.090 |
Why?
|
| Regression Analysis | 1 | 2020 | 6331 | 0.090 |
Why?
|
| Secondary Prevention | 1 | 2017 | 1472 | 0.090 |
Why?
|
| Pain Measurement | 1 | 2020 | 3584 | 0.080 |
Why?
|
| Cardiovascular System | 1 | 2017 | 839 | 0.080 |
Why?
|
| C-Reactive Protein | 1 | 2020 | 3851 | 0.080 |
Why?
|
| Public Health | 1 | 2020 | 2681 | 0.070 |
Why?
|
| Prevalence | 1 | 2024 | 15851 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2011 | 12250 | 0.070 |
Why?
|
| Rheumatic Diseases | 1 | 2014 | 659 | 0.070 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 7848 | 0.070 |
Why?
|
| Middle Aged | 5 | 2024 | 223233 | 0.060 |
Why?
|
| Autoantibodies | 1 | 2014 | 2114 | 0.060 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2020 | 3778 | 0.060 |
Why?
|
| Inpatients | 1 | 2016 | 2563 | 0.060 |
Why?
|
| Adult | 4 | 2024 | 223317 | 0.050 |
Why?
|
| Insulin | 1 | 2017 | 6602 | 0.050 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 12069 | 0.050 |
Why?
|
| Length of Stay | 1 | 2016 | 6489 | 0.050 |
Why?
|
| Autoimmune Diseases | 1 | 2014 | 2255 | 0.050 |
Why?
|
| Logistic Models | 1 | 2016 | 13284 | 0.050 |
Why?
|
| Pandemics | 1 | 2020 | 8736 | 0.040 |
Why?
|
| Colchicine | 1 | 2020 | 256 | 0.040 |
Why?
|
| Diabetes Mellitus | 1 | 2017 | 5886 | 0.040 |
Why?
|
| Allopurinol | 1 | 2020 | 202 | 0.040 |
Why?
|
| Male | 4 | 2024 | 364203 | 0.040 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2020 | 228 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2016 | 22254 | 0.040 |
Why?
|
| Aged | 2 | 2024 | 171319 | 0.040 |
Why?
|
| Obesity | 1 | 2020 | 13085 | 0.040 |
Why?
|
| Scleroderma, Localized | 1 | 2017 | 85 | 0.030 |
Why?
|
| Immunoproliferative Disorders | 1 | 2014 | 2 | 0.030 |
Why?
|
| Cryoglobulins | 1 | 2014 | 58 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2011 | 10393 | 0.030 |
Why?
|
| Female | 3 | 2024 | 396660 | 0.030 |
Why?
|
| Immunologic Tests | 1 | 2014 | 101 | 0.030 |
Why?
|
| Biological Factors | 1 | 2014 | 155 | 0.030 |
Why?
|
| Urticaria | 1 | 2014 | 151 | 0.030 |
Why?
|
| Antibodies, Antinuclear | 1 | 2014 | 340 | 0.020 |
Why?
|
| Morbidity | 1 | 2017 | 1754 | 0.020 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2014 | 297 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2016 | 59548 | 0.020 |
Why?
|
| Complement System Proteins | 1 | 2014 | 738 | 0.020 |
Why?
|
| Fibrosis | 1 | 2017 | 2078 | 0.020 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 2270 | 0.020 |
Why?
|
| Vasculitis | 1 | 2014 | 526 | 0.020 |
Why?
|
| Disease Management | 1 | 2020 | 2531 | 0.020 |
Why?
|
| Risk Factors | 1 | 2016 | 74886 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2020 | 12451 | 0.020 |
Why?
|
| Diet | 1 | 2021 | 8089 | 0.010 |
Why?
|
| Animals | 1 | 2011 | 168965 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 14672 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 12986 | 0.010 |
Why?
|